Last 47 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -103.14 | — | — | — | 33.76 | 35.38 | 77.78 | — | 37.28 | 29.68 | 52.11 | 16.33 | 28.99 | 27.81 | 25.10 | 14.92 | 24.93 | 26.56 | 38.55 | 35.28 | 57.00 |
| — | — | — | — | -9.4% | +19.2% | +49.3% | — | +28.6% | +6.7% | +107.6% | +9.4% | +16.3% | +4.7% | -34.9% | -57.7% | -56.3% | -50.3% | -35.8% | +58.7% | +113.5% | |
| P/S Ratio | 3.60 | 2.60 | 1.96 | 2.52 | 1.83 | 1.79 | 2.01 | 2.35 | 2.53 | 2.61 | 3.47 | 3.01 | 2.46 | 2.55 | 2.52 | 2.54 | 2.43 | 2.98 | 3.92 | 5.37 | 6.59 |
| — | +45.4% | -2.7% | +7.1% | -27.9% | -31.3% | -42.1% | -21.8% | +2.8% | +2.2% | +37.7% | +18.3% | +1.3% | -14.4% | -35.7% | -52.6% | -63.1% | -42.2% | -12.2% | +33.2% | +78.4% | |
| P/B Ratio | 4.63 | 3.68 | 2.61 | 3.12 | 2.13 | 2.18 | 2.44 | 2.69 | 2.67 | 2.84 | 3.79 | 3.34 | 3.02 | 3.28 | 3.29 | 3.70 | 3.60 | 4.31 | 5.36 | 7.49 | 9.59 |
| — | +68.9% | +6.8% | +16.0% | -20.4% | -23.3% | -35.7% | -19.3% | -11.5% | -13.4% | +15.3% | -9.9% | -16.1% | -23.9% | -38.7% | -50.6% | -62.5% | -46.3% | -19.2% | +26.0% | +68.0% | |
| P/FCF | 27.88 | 17.60 | — | 42.78 | 10.30 | 10.92 | 17.60 | 28.18 | 12.00 | 17.38 | 69.20 | 21.39 | 18.12 | 33.51 | 1034.61 | 19.20 | 39.81 | 43.55 | 161.56 | 37.22 | 49.56 |
| — | +61.1% | — | +51.8% | -14.2% | -37.2% | -74.6% | +31.7% | -33.8% | -48.1% | -93.3% | +11.4% | -54.5% | -23.1% | +540.4% | -48.4% | -19.7% | +29.3% | +524.7% | -41.0% | +172.6% | |
| EV / EBITDA | 19.00 | 17.76 | 14.24 | 16.22 | 11.15 | 11.38 | 13.67 | — | 15.54 | 14.06 | 19.87 | 17.56 | 13.96 | 14.12 | 13.61 | 14.56 | 14.16 | 14.04 | 19.04 | 23.32 | 29.61 |
| — | +56.0% | +4.2% | — | -28.2% | -19.0% | -31.2% | — | +11.3% | -0.4% | +46.0% | +20.6% | -1.4% | +0.6% | -28.5% | -37.5% | -52.2% | -46.7% | -15.3% | +20.6% | +76.1% | |
| EV / EBIT | 34.08 | 39.81 | — | — | 21.68 | 24.66 | 41.76 | — | 26.29 | 21.93 | 31.34 | 15.47 | 21.93 | 20.92 | 20.16 | 12.57 | 23.75 | 25.06 | 35.47 | 31.95 | 47.57 |
| — | +61.4% | — | — | -17.5% | +12.5% | +33.3% | — | +19.9% | +4.8% | +55.4% | +23.1% | -7.7% | -16.5% | -43.2% | -60.7% | -50.1% | -33.5% | -18.2% | +79.0% | +126.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 36.2% | 28.0% | 31.0% | 33.7% | 34.6% | 32.3% | 28.4% | 34.6% | 34.5% | 34.1% | 35.9% | 35.2% | 37.6% | 36.7% | 36.3% | 37.4% | 36.7% | 36.9% | 38.4% | 37.6% |
| — | +4.6% | -13.1% | +9.2% | -2.5% | +0.4% | -5.3% | -21.1% | -1.9% | -8.4% | -7.1% | -0.9% | -5.8% | +2.7% | -0.5% | -5.4% | -0.6% | -2.0% | -1.4% | +1.1% | -3.3% | |
| Operating Margin | 12.6% | 11.9% | 12.0% | 12.1% | 13.3% | 9.7% | 7.6% | -16.7% | 11.6% | 14.8% | 12.5% | 13.1% | 14.8% | 15.6% | 16.3% | 14.9% | 15.3% | 19.3% | 16.3% | 19.1% | 17.4% |
| — | +23.1% | +58.7% | +172.3% | +14.5% | -34.4% | -39.1% | -227.5% | -21.2% | -5.0% | -23.6% | -11.9% | -3.3% | -19.2% | +0.2% | -22.0% | -12.2% | +28.1% | +8.5% | +17.1% | -2.6% | |
| Net Margin | -3.6% | -0.1% | -1.5% | -27.8% | 5.4% | 5.1% | 2.6% | -21.5% | 6.8% | 8.8% | 6.7% | 18.5% | 8.5% | 9.2% | 10.0% | 17.0% | 9.8% | 11.2% | 10.2% | 15.2% | 11.5% |
| — | -102.9% | -157.6% | -29.3% | -20.4% | -42.2% | -61.1% | -216.6% | -20.1% | -4.2% | -33.6% | +8.3% | -12.7% | -18.5% | -1.6% | +12.1% | -15.5% | +16.2% | +36.4% | -16.0% | -16.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.3% | -0.1% | -0.5% | -8.3% | 1.6% | 1.6% | 0.8% | -5.9% | 1.8% | 2.4% | 1.8% | 5.3% | 2.6% | 3.0% | 3.3% | 6.6% | 3.6% | 4.1% | 3.5% | 5.4% | 4.3% |
| — | -103.2% | -163.4% | -41.2% | -12.1% | -34.5% | -58.7% | -210.2% | -31.2% | -19.9% | -45.2% | -18.9% | -26.9% | -26.3% | -5.6% | +20.9% | -16.2% | +5.3% | +25.2% | -22.7% | -22.7% | |
| ROA | -2.0% | -0.0% | -0.2% | -3.8% | 0.7% | 0.7% | 0.3% | -2.8% | 0.9% | 1.1% | 0.8% | 2.4% | 1.1% | 1.3% | 1.3% | 2.5% | 1.3% | 1.5% | 1.3% | 2.0% | 1.5% |
| — | -102.8% | -159.2% | -35.9% | -16.2% | -38.2% | -59.1% | -217.3% | -24.2% | -10.9% | -38.9% | -5.3% | -12.2% | -16.2% | +2.2% | +28.0% | -13.8% | +6.0% | +21.2% | -27.0% | -23.8% | |
| ROIC | 6.3% | 1.6% | 1.5% | 1.5% | 1.7% | 1.3% | 0.9% | -2.0% | 1.4% | 1.8% | 1.5% | 1.6% | 1.9% | 2.0% | 2.1% | 2.1% | 1.9% | 2.5% | 2.0% | 2.4% | 2.2% |
| — | +24.6% | +62.2% | +174.6% | +22.9% | -29.1% | -36.5% | -227.5% | -25.7% | -12.3% | -30.2% | -24.2% | -4.1% | -19.0% | +3.1% | -11.2% | -12.8% | +11.9% | -9.7% | -3.0% | -14.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 1.06 | 1.02 | 0.95 | 0.76 | 0.82 | 0.92 | 0.78 | 0.72 | 0.75 | 0.83 | 0.84 | 0.87 | 0.93 | 1.00 | 1.02 | 1.25 | 1.27 | 1.12 | 1.24 | 1.29 |
| — | +29.8% | +11.0% | +22.9% | +5.8% | +9.0% | +10.8% | -7.3% | -16.8% | -19.4% | -17.0% | -18.2% | -30.9% | -26.4% | -10.3% | -17.2% | -2.5% | -0.6% | +2.9% | +22.7% | +13.2% | |
| Debt / EBITDA | 3.36 | 16.18 | 16.34 | 15.44 | 12.02 | 12.68 | 15.31 | — | 13.42 | 11.94 | 14.57 | 14.37 | 12.61 | 12.70 | 12.91 | 12.83 | 14.86 | 12.94 | 13.30 | 13.35 | 14.12 |
| — | +27.5% | +6.7% | — | -10.5% | +6.3% | +5.1% | — | +6.4% | -6.0% | +12.9% | +12.0% | -15.2% | -1.9% | -3.0% | -3.9% | +5.2% | -11.3% | +2.5% | +17.3% | +24.2% | |
| Current Ratio | 1.29 | 1.35 | 1.36 | 1.29 | 1.37 | 1.36 | 1.43 | 1.41 | 1.48 | 1.58 | 1.75 | 1.52 | 1.45 | 1.49 | 1.48 | 1.32 | 1.40 | 1.33 | 1.34 | 1.23 | 1.40 |
| — | -0.9% | -5.0% | -8.5% | -7.5% | -14.0% | -18.0% | -7.4% | +1.6% | +6.0% | +18.4% | +15.7% | +4.1% | +12.4% | +10.0% | +6.9% | -0.4% | -2.6% | -24.3% | -13.8% | -3.2% | |
| Quick Ratio | 1.02 | 1.04 | 1.03 | 1.02 | 1.10 | 1.10 | 1.16 | 1.13 | 1.14 | 1.21 | 1.37 | 1.16 | 1.16 | 1.21 | 1.21 | 1.08 | 1.14 | 1.08 | 1.12 | 1.04 | 1.22 |
| — | -5.4% | -10.8% | -9.4% | -4.2% | -9.2% | -15.5% | -2.8% | -1.2% | +0.3% | +13.3% | +7.4% | +1.8% | +11.6% | +8.0% | +4.2% | -6.5% | -6.1% | -26.9% | -14.0% | -0.1% | |
| Interest Coverage | 0.07 | 2.75 | -0.12 | -11.37 | 4.43 | 3.38 | 2.29 | -6.68 | 4.01 | 4.65 | 3.83 | 7.22 | 4.35 | 4.67 | 4.81 | 8.04 | 11.82 | 39.92 | 12.75 | 15.17 | 8.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRL stock.
Charles River Laboratories International, Inc.'s current P/E is -103.1x. The average P/E over the last 1 quarters is 33.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Charles River Laboratories International, Inc.'s current operating margin is 12.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Charles River Laboratories International, Inc.'s business trajectory between earnings reports.